Vitamin D Deficiency Clinical Trial
Official title:
The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain
Vitamin D3 is produced in the skin following exposure to UVB light from the sun or
artificial sources, and occurs naturally in a small range of foods.More recently, several
reports underlined the impact of vitamin D on the prevalence and consequences of inadequate
vitamin D intake and the research supporting its benefits for alleviating chronic
musculoskeletal pain and fatigue syndromes in outpatients. Experts have recommended that
vitamin D inadequacy should be addressed in all patients with bone or joint pain, myalgia,
fibromyalgia, or chronic fatigue syndrome. It appears that soothing the daily
musculoskeletal pain by supplementation of vitamin D may be a simple, well tolerated, and
cost-effective modality.
Aim of study:
To study the potential therapeutic effects of vitamin D supplementation on patients with
persistent musculo-skeletal pain. Clinicalparameters, visual analog score,short form McGill
Pain Questionnaire,patient global perceived effect, quality of life assessed by SF-36
Questionnaire and laboratory parameters, the levels of 25 OH-Vitamin D, CRP, IL-6, IL-8, TNF
and prostaglandin E will be assessed.
The immune and clinical impacts of vitamin D in patients with chronic musculo-skeletal pain
Background Vitamin D is a group of fat-soluble secosteroids, the two major physiologically
relevant forms are vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol). Vitamin D
without a subscript refers to either D2 or D3 or both. Vitamin D3 is produced in the skin
following exposure to UVB light from the sun or artificial sources, and occurs naturally in
a small range of foods. Vitamin D is carried in the bloodstream to the liver, where it is
converted into the prohormone calcidiol. Circulating calcidiol may then be converted into
calcitriol, the biologically active form of vitamin D, either in the kidneys or by
monocyte-macrophages in the immune system. When synthesized by monocyte-macrophages,
calcitriol acts locally as a cytokine, defending the body against microbial invaders (1).
When synthesized in the kidneys, calcitriol circulates as a hormone, regulating among other
things, the concentration of calcium and phosphate in the bloodstream, promoting the healthy
mineralization, growth and remodeling of bone, and also vital to the normal function of the
different arms of the immune system (1;2).
Vitamin D receptor activation in the intestine, bone, kidney, and parathyroid gland cells
leads to the maintenance of calcium and phosphorus levels in the blood (with the assistance
of parathyroid hormone and calcitonin) and to the maintenance of bone content. Vitamin D
increases expression of the tyrosine hydroxylase gene in adrenal medullary cells. Vitamin D
is involved in the biosynthesis of neurotrophic factors, synthesis of nitric oxide synthase,
and increased glutathione levels. Adequate vitamin D may also be associated with healthy
hair follicle growth cycles (3). Vitamin D insufficiency can result in thin and brittle
bones, whereas sufficiency prevents rickets in children and osteomalacia in adults and helps
to protect elderly from osteoporosis. Vitamin D has also direct on muscle strength and
function (4;5). Nevertheless, there is no persuasive evidence of lower vitamin D status in
chronic pain sufferers.
There are also associations between low 25(OH)D levels and peripheral vascular disease (6),
certain cancers (7-10), multiple sclerosis (11), rheumatoid arthritis (12-15), juvenile
diabetes (16-18), Parkinson's and Alzheimer's disease (19;20). However these associations
were found in observational studies and vitamin D vitamin supplements have not been
demonstrated to reduce the risks of these diseases.
More recently, several reports underlined the impact of vitamin D on the prevalence and
consequences of inadequate vitamin D intake and the research supporting its benefits for
alleviating chronic musculoskeletal pain and fatigue syndromes in outpatients. There are
extensive reports of pain worldwide and much of it is chronic, lasting 3 or more months,
primarily involving muscles, bones and joints. In the United States, more than half of all
adults participating in surveys have reported long term persistent or intermittent pain,
with the lower and upper back, neck, shoulders, hips, and knees mentioned most frequently
(21). For lower-back pain alone, an annual incidence of 50% and a lifetime prevalence of up
to 80% have been reported (22). In more than 8 out of 10 cases, the causes are nonspecific,
without evidence of injury, disease, or anatomical defect (23;24). More than a quarter (28%)
of patients with chronic pain rate the effectiveness of medical treatments as poor, and most
(77%) believe that new options are needed to treat their pain (25-27). It appears that
soothing the daily musculoskeletal pain by supplementation of vitamin D may be a simple,
well tolerated, and cost-effective modality. Experts have recommended that vitamin D
inadequacy should be addressed in all patients with bone or joint pain, myalgia,
fibromyalgia, or chronic fatigue syndrome (28;29). However, this seems to be unknown or
overlooked by many healthcare providers. Research on vitamin D is still an emerging field,
and there are divergent opinions among experts regarding many aspects of vitamin D
pharmacology, function, and adequate intake needed for good health. While further research
is needed, the clinical evidence to date recommending vitamin D supplementation for
musculoskeletal pain and associated symptoms seems to be growing. In 3670 patients taking
part in different studies with musculoskeletal pain significant vitamin D inadequacies were
found in 48% to 100%. A study from the Mayo Clinic reported that a whopping 93% of patients
with "chronic nonspecific pain syndromes" had deficient levels of vitamin D (30). When
supplementation was provided for improving vitamin D status, pain and/or muscle weakness
were resolved or at least subsided in most cases, and there were associated improvements in
physical functioning.
A recently reported prospective study of 51 patients with type 2 diabetes and associated
chronic, painful neuropathy found that conservative vitamin D supplementation (about 2000
IU/day) for 3 months resulted in nearly a 50% decrease in pain scores, with symptoms
improving from "distressing" to "mild" on average (31). There had been an earlier case
report of a patient with type 1 diabetes whose severe neuropathy had confined her to a
wheelchair. This patient's aches and pains were resolved by high-dose vitamin D
supplementation, and she reportedly was able to walk unassisted within 4 weeks (32). Other
therapies need not be discontinued during a trial of vitamin D "analgesia.
Miller et al (33) evaluated in a cohort from the Baltimore Hip Studies, women aged >65 years
were at baseline and 2, 6, and 12 months after hip fracture repair. Serum at baseline was
analyzed for 25-hydroxyvitamin D [25(OH)D] and serum from all time points was analyzed for
IL-6, women with vitamin D deficiency at the time of hip fracture had higher serum IL-6
levels in the year after hip fracture.
Aim of study To study the potential therapeutic effects of vitamin D supplementation on
patients with persistent musculo-skeletal pain. Clinical and laboratory parameters will be
assessed.
Methods We enrolled 80 patients of the age 18-80 years suffering from chronic
musculo-skeletal pain (low back pain, fibromyalgia, chronic widespread pain) at least 6
months. The enrollees will be randomized in a double-blinded manner into the two following
groups: Group 1 will receive daily doses of 4000 units of vitamin D ( 4 drops of 1,000 each)
and Group 2 will receive a placebo. Written informed consent will be obtained from all
participating patients.
On the day of recruitment blood will be drawn in order to determine the levels of 25
OH-Vitamin D, CRP, IL-6, IL-8, TNF and prostaglandin E2. Vitamin D or placebo will be taken
for 6 weeks on top of the individual's daily medications. A second blood analysis will be
conducted following the 6 week duration.
Additional outcome measures pain intensity assessed by visual analog score (VAS) (0 = no
pain, 10 = worst imaginable pain), short form McGill Pain Questionnaire (SMPQ), patient
global perceived effect (PGPE), scored by the patient on a 7-point Likert scale (from very
bad to very good), quality of life assessed by SF-36 Questionnaire will be evaluated at base
line, 6 weeks, 12 weeks and 6 months after the inclusion . At 12 weeks period a third 25
OH-Vitamin D blood level will be measured. Rescue medication will be provided as paracetamol
325mg+codein 15 mg. Consumption of pain medication will be recorded during the study and 2
week intervals. Adverse events will be recorded on each 6 weeks period and on patient
report.
The vitamin D levels will be assessed by using the commercial kit, LIAISON® 25-OH vitamin D
Assay (310900) (Cardinal Health, Inc., Dublin, OH, USA). The method for quantitative
determination of 25-OH vitamin D is a direct, competitive chemiluminescence immunoassay.
The other assays will be assessed by ELISA kits. Statistics will be performed using the SPSS
18th edition using the Student's t-test or the Chi-Square test and if appropriate with
Fisher's exact test. To adjust for differences in the baseline values, the analyses will be
performed by using a multivariate logistic regression model. Consumption of medication will
be compared using the Man-Whitney U test. Significance will be regarded if the p values will
be lower than 0.05.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Recruiting |
NCT05459298 -
ViDES Trial (Vitamin D Extra Supplementation)
|
N/A | |
Completed |
NCT04476511 -
The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules
|
Phase 3 | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03920150 -
Vitamin D 24'000 IU for Oral Intermittent Supplementation
|
Phase 3 | |
Completed |
NCT03264625 -
The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis
|
Phase 2 | |
Completed |
NCT04183257 -
Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics
|
Phase 4 | |
Recruiting |
NCT05084248 -
Vitamin D Deficiency in Adults Following a Major Burn Injury
|
Phase 4 | |
Completed |
NCT05506696 -
Vitamin D Supplementation Study
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Completed |
NCT03234218 -
Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
|
||
Completed |
NCT02714361 -
A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women
|
N/A | |
Completed |
NCT03203382 -
Corneal Nerve Structure in Sjogren's
|
||
Completed |
NCT02906319 -
Vitamin D and HbA1c Levels in Diabetic Patients With CKD
|
N/A | |
Completed |
NCT02118129 -
Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.
|
N/A | |
Completed |
NCT02187146 -
The Effects of Serum Vitamin D and IVF Outcome
|
N/A | |
Completed |
NCT02275650 -
The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter
|
N/A | |
Not yet recruiting |
NCT01419821 -
Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5
|
N/A | |
Completed |
NCT01741181 -
Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2
|
Phase 4 | |
Completed |
NCT01651000 -
Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
|
Phase 3 |